Neuroleptics, the most widely prescribed group of psychotropic drugs, are indispensable in the management of a majority of patients with schizophrenia, as well as other psychoses, yet they have not proved to be an unmixed blessing. They are associated with troublesome adverse effects, of which movement disorders are the most serious in terms of frequency, persistence and overall impact on the well-being of patients and care-givers. This book was prepared with the aim of improving understanding and clinical management of these iatrogenic conditions. It deals with historical, clinical and…mehr
Neuroleptics, the most widely prescribed group of psychotropic drugs, are indispensable in the management of a majority of patients with schizophrenia, as well as other psychoses, yet they have not proved to be an unmixed blessing. They are associated with troublesome adverse effects, of which movement disorders are the most serious in terms of frequency, persistence and overall impact on the well-being of patients and care-givers. This book was prepared with the aim of improving understanding and clinical management of these iatrogenic conditions. It deals with historical, clinical and neurobiological aspects of tardive dyskinesia and related movement disorders such as parkinsonism, dystonia and akathisia. Sections are also devoted to the measurement of tardive dyskinesia, to geographical and ethnic differences, and to management with novel neuroleptic agents and biofeedback. With authoritative contributions and an international perspective, this book will be valuable to clinicians and researchers alike in psychiatry, neurology and related disciplines.
Contributors; Preface; Part I. Historical Perspective: 1. Neuroleptic-induced movement disorders: historical perspective Marc-Alain Wolf, Ramzy Yassa and Pierre-Michel Llorca; Part II. Clinical Aspects of Tardive Dyskinesia: 2. Aging and tardive dyskinesia Bruce L. Saltz, John M. Kane, Margaret G. Woerner, Jeffrey A. Lieberman and José Ma. J. Alvir; 3. Gender as a factor in the development of tardive dyskinesia Ramzy Yassa and Dilip V. Jeste; 4. The Yale tardive dyskinesia study: a prospective incidence study among long-term outpatients William M. Glazer, Hal Morgenstern, Donna Raye Wagner and John Doucette; 5. Vulnerability to tardive dyskinesia in schizophrenia: an exploration of individual patient factors John L. Waddington, Eadbhard O'Callaghan, Peter Buckely, Cathy Madigan, Conall Larkin and Anthony Kinsella; 6. Tardive dyskinesia and affective disorder George Gardos and Jonathan O. Cole; 7. Diabetes mellitus and tardive dyskinesia Sukdeb Mukherjee and Sahebarao P. Mahadik; 8. Other factors in the development of tardive dyskinesia Ramzy Yassa; 9. Neuroleptic treatment and tardive dyskinesia George Gardos and Jonathan O. Cole; 10. Anticholinergic drugs as factors in the development of tardive dyskinesia Ramzy Yassa and N. P. V. Nair; Part III. Mechanisms Underlying Tardive Dyskinesia: 11. Neurochemistry of the basal ganglia N. P. V. Nair and T. E. G. West; 12. A reanalysis of the dopamine theory of tardive dyskinesia: the hypothesis of dopamine D1/D2 imbalance Linda Peacock and Jes Gerlach; 13. Tardive dyskinesia and phenylalanine metabolism: risk-factor studies Mary Ann Richardson, Cheryl Flynn, Laura Read, Margaret Reilly and Raymond Suckow; 14. Neuroendocrinological studies of tardive dyskinesia Margot Albus; 15. Cognitive deficits and tardive dyskinesia Marion E. Wolf, Alan S. DeWolfe and Aron D. Mosnaim; 16. Studies of tardive dyskinesia using computed tomography and magnetic-resonance imaging Christian L. Shriqui; 17. Rodent and other animal models of tardive dyskinesia during long-term neuroleptic-drug administration: controversies and implications for the clinical syndrome John L. Waddington; Part IV. Measurement of Tardive Dyskinesia: 18. Instrument measurements of tardive dyskinesia Michael P. Caligiuri; Part V. Tardive Dyskinesia in Different Populations: 19. Cultural aspects of tardive dyskinesia in Asia Shigeto Yamawaki, Teruo Hayashi; Ikuo Nagaoka, Hiroshi Saitoh, Norio Yokota and Yosuke Uchitomi; 20. Tardive dyskinesia in North America and the Middle East Driss Moussaoui; 21. Tardive dyskinesia in Europe H. A. McClelland and T. A. Kerr; 22. Role of ethnicity in the development of tardive dyskinesia Jonathan P. Lacro and Dilip V. Jeste; 23. Tardive dyskinesia in children and adolescents Mark Magulac and Dilip V. Jeste; Part VI. Other Neuropleptic-Induced Movement Disorders: 24. Drug-induced parkinsonism Thomas E. Hansen and William F. Hoffman; 25. Clinical aspects of neuroleptic-induced dystonia George A. Keepers and Linda Ganzini; 26. Tardive dystonia Paul Greene; 27. Tardive akathisia Robert E. Burke; Part VII. Treatment of Tardive Dyskinesia: 28. Development of novel antipsychotic drugs with reduced extrapyramidal side effects Allan Z. Safferman, Jeffrey A. Lieberman, Bruce J. Kinon, Daniel Umbricht, Jeffrey S. Aronowitz and John M. Kane; 29. GABAergic treatments for tardive dyskinesia Shawn L. Cassady, Gunvant K. Thaker and Carol A. Tamminga; 30. Using biofeedback to train suppression of the oral-lingual movements of tardive dyskinesia Ronald C. Fudge and Cecile E. Sison; Index.
Contributors; Preface; Part I. Historical Perspective: 1. Neuroleptic-induced movement disorders: historical perspective Marc-Alain Wolf, Ramzy Yassa and Pierre-Michel Llorca; Part II. Clinical Aspects of Tardive Dyskinesia: 2. Aging and tardive dyskinesia Bruce L. Saltz, John M. Kane, Margaret G. Woerner, Jeffrey A. Lieberman and José Ma. J. Alvir; 3. Gender as a factor in the development of tardive dyskinesia Ramzy Yassa and Dilip V. Jeste; 4. The Yale tardive dyskinesia study: a prospective incidence study among long-term outpatients William M. Glazer, Hal Morgenstern, Donna Raye Wagner and John Doucette; 5. Vulnerability to tardive dyskinesia in schizophrenia: an exploration of individual patient factors John L. Waddington, Eadbhard O'Callaghan, Peter Buckely, Cathy Madigan, Conall Larkin and Anthony Kinsella; 6. Tardive dyskinesia and affective disorder George Gardos and Jonathan O. Cole; 7. Diabetes mellitus and tardive dyskinesia Sukdeb Mukherjee and Sahebarao P. Mahadik; 8. Other factors in the development of tardive dyskinesia Ramzy Yassa; 9. Neuroleptic treatment and tardive dyskinesia George Gardos and Jonathan O. Cole; 10. Anticholinergic drugs as factors in the development of tardive dyskinesia Ramzy Yassa and N. P. V. Nair; Part III. Mechanisms Underlying Tardive Dyskinesia: 11. Neurochemistry of the basal ganglia N. P. V. Nair and T. E. G. West; 12. A reanalysis of the dopamine theory of tardive dyskinesia: the hypothesis of dopamine D1/D2 imbalance Linda Peacock and Jes Gerlach; 13. Tardive dyskinesia and phenylalanine metabolism: risk-factor studies Mary Ann Richardson, Cheryl Flynn, Laura Read, Margaret Reilly and Raymond Suckow; 14. Neuroendocrinological studies of tardive dyskinesia Margot Albus; 15. Cognitive deficits and tardive dyskinesia Marion E. Wolf, Alan S. DeWolfe and Aron D. Mosnaim; 16. Studies of tardive dyskinesia using computed tomography and magnetic-resonance imaging Christian L. Shriqui; 17. Rodent and other animal models of tardive dyskinesia during long-term neuroleptic-drug administration: controversies and implications for the clinical syndrome John L. Waddington; Part IV. Measurement of Tardive Dyskinesia: 18. Instrument measurements of tardive dyskinesia Michael P. Caligiuri; Part V. Tardive Dyskinesia in Different Populations: 19. Cultural aspects of tardive dyskinesia in Asia Shigeto Yamawaki, Teruo Hayashi; Ikuo Nagaoka, Hiroshi Saitoh, Norio Yokota and Yosuke Uchitomi; 20. Tardive dyskinesia in North America and the Middle East Driss Moussaoui; 21. Tardive dyskinesia in Europe H. A. McClelland and T. A. Kerr; 22. Role of ethnicity in the development of tardive dyskinesia Jonathan P. Lacro and Dilip V. Jeste; 23. Tardive dyskinesia in children and adolescents Mark Magulac and Dilip V. Jeste; Part VI. Other Neuropleptic-Induced Movement Disorders: 24. Drug-induced parkinsonism Thomas E. Hansen and William F. Hoffman; 25. Clinical aspects of neuroleptic-induced dystonia George A. Keepers and Linda Ganzini; 26. Tardive dystonia Paul Greene; 27. Tardive akathisia Robert E. Burke; Part VII. Treatment of Tardive Dyskinesia: 28. Development of novel antipsychotic drugs with reduced extrapyramidal side effects Allan Z. Safferman, Jeffrey A. Lieberman, Bruce J. Kinon, Daniel Umbricht, Jeffrey S. Aronowitz and John M. Kane; 29. GABAergic treatments for tardive dyskinesia Shawn L. Cassady, Gunvant K. Thaker and Carol A. Tamminga; 30. Using biofeedback to train suppression of the oral-lingual movements of tardive dyskinesia Ronald C. Fudge and Cecile E. Sison; Index.
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826
